CalciMedica (NASDAQ:CALC – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.
CalciMedica Stock Performance
CalciMedica stock opened at $2.04 on Thursday. CalciMedica has a 52-week low of $1.83 and a 52-week high of $6.27. The firm has a 50 day moving average price of $2.52 and a two-hundred day moving average price of $3.29. The firm has a market cap of $27.50 million, a price-to-earnings ratio of -1.89 and a beta of 1.20.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of CalciMedica in a report on Tuesday, March 4th.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Articles
- Five stocks we like better than CalciMedica
- 3 Tickers Leading a Meme Stock Revival
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- How to Invest in Insurance Companies: A Guide
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Short Selling: How to Short a Stock
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
